Authorization

Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York

LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (a??Verona Pharmaa??), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, and Piers Morgan, CFO, will participate in two institutional investor conferences later this month.
Details on the conference appearances are as follows:Guggenheim Healthcare Talks Idea Forum | Neuro/Immunology Day
Date: Monday, November 18, 2019
Location: New York, NYStifel 2019 Healthcare Conference
Presenter: Jan-Anders Karlsson, CEO
Date: Tuesday, November 19, 2019
Presentation: 8:00 AM ET
Location: New York, NYAbout Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharmaa??s product candidate, ensifentrine, has the potential to be the first novel class of bronchodilator in over 40 years, and the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently in Phase 2 development of three formulations of ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
242526272829